Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1958 1
1971 1
1976 1
1979 1
1980 1
1982 4
1983 1
1984 3
1985 3
1986 6
1987 18
1988 42
1989 30
1990 41
1991 37
1992 50
1993 55
1994 41
1995 54
1996 56
1997 56
1998 40
1999 63
2000 51
2001 67
2002 62
2003 61
2004 69
2005 66
2006 90
2007 72
2008 87
2009 72
2010 83
2011 105
2012 123
2013 144
2014 260
2015 365
2016 383
2017 432
2018 454
2019 494
2020 561
2021 608
2022 575
2023 562
2024 232

Text availability

Article attribute

Article type

Publication date

Search Results

5,783 results

Results by year

Filters applied: . Clear all
Page 1
Overnight Stay in the Emergency Department and Mortality in Older Patients.
Roussel M, Teissandier D, Yordanov Y, Balen F, Noizet M, Tazarourte K, Bloom B, Catoire P, Berard L, Cachanado M, Simon T, Laribi S, Freund Y; FHU IMPEC-IRU SFMU Collaborators; FHU IMPEC−IRU SFMU Collaborators. Roussel M, et al. JAMA Intern Med. 2023 Dec 1;183(12):1378-1385. doi: 10.1001/jamainternmed.2023.5961. JAMA Intern Med. 2023. PMID: 37930696
DESIGN, SETTINGS, AND PARTICIPANTS: This was a prospective cohort study of older patients (75 years) who visited the ED and were admitted to the hospital on December 12 to 14, 2022, at 97 EDs across France. Two groups were defined and compared: those who stayed in the ED f …
DESIGN, SETTINGS, AND PARTICIPANTS: This was a prospective cohort study of older patients (75 years) who visited the ED and were admitted to …
Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial.
Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group. Conroy T, et al. Lancet Oncol. 2014 Mar;15(3):305-14. doi: 10.1016/S1470-2045(14)70028-2. Epub 2014 Feb 18. Lancet Oncol. 2014. PMID: 24556041 Clinical Trial.
FINDINGS: 134 participants were randomly allocated to the FOLFOX group and 133 to the fluorouracil and cisplatin group (intention-to-treat population), and 131 patients in the FOLFOX group and 128 in the fluorouracil and cisplatin group actually …
FINDINGS: 134 participants were randomly allocated to the FOLFOX group and 133 to the fluorouracil and cisplatin group (intent …
Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial.
Grupp SA, Corbacioglu S, Kang HJ, Teshima T, Khaw SL, Locatelli F, Maertens J, Stelljes M, Stepensky P, Lopez P, Amber V, Pagliuca A, Richardson PG, Mohty M. Grupp SA, et al. Lancet Haematol. 2023 May;10(5):e333-e345. doi: 10.1016/S2352-3026(23)00011-X. Epub 2023 Mar 28. Lancet Haematol. 2023. PMID: 37001534 Clinical Trial.
FINDINGS: Between Jan 11, 2017, and Oct 20, 2020, 372 patients (172 [46%] women and 200 [54%] men; median age 14.0 years [IQR 4.0-41.0] were randomly assigned to the defibrotide prophylaxis group (n=190) or best supportive care group (n=182; ITT population). …
FINDINGS: Between Jan 11, 2017, and Oct 20, 2020, 372 patients (172 [46%] women and 200 [54%] men; median age 14.0 years [IQR 4.0-41.0] were …
Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial.
André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F, de Gramont A. André T, et al. J Clin Oncol. 2009 Jul 1;27(19):3109-16. doi: 10.1200/JCO.2008.20.6771. Epub 2009 May 18. J Clin Oncol. 2009. PMID: 19451431 Clinical Trial.
Results Five-year DFS rates were 73.3% and 67.4% in the FOLFOX4 and LV5FU2 groups, respectively (hazard ratio [HR] = 0.80; 95% CI, 0.68 to 0.93; P = .003). ...No difference in OS was seen in the stage II population. The incidence of second noncolorectal cancers was …
Results Five-year DFS rates were 73.3% and 67.4% in the FOLFOX4 and LV5FU2 groups, respectively (hazard ratio [HR] = 0.80; 95% CI, 0. …
Inflammatory sensory neuronopathies.
Antoine JC. Antoine JC. Rev Neurol (Paris). 2024 Mar 11:S0035-3787(24)00455-7. doi: 10.1016/j.neurol.2023.12.012. Online ahead of print. Rev Neurol (Paris). 2024. PMID: 38472032 Review.
Inflammatory sensory neuronopathies are rare disorders mediated by dysimmune mechanisms targeting sensory neurons in the dorsal root ganglia. They constitute a heterogeneous group of disorders with acute, subacute, or chronic courses, and occur with cancer, systemic autoim …
Inflammatory sensory neuronopathies are rare disorders mediated by dysimmune mechanisms targeting sensory neurons in the dorsal root ganglia …
Interactive telemedicine: effects on professional practice and health care outcomes.
Flodgren G, Rachas A, Farmer AJ, Inzitari M, Shepperd S. Flodgren G, et al. Cochrane Database Syst Rev. 2015 Sep 7;2015(9):CD002098. doi: 10.1002/14651858.CD002098.pub2. Cochrane Database Syst Rev. 2015. PMID: 26343551 Free PMC article. Review.
SEARCH METHODS: We searched the Effective Practice and Organisation of Care (EPOC) Group's specialised register, CENTRAL, MEDLINE, EMBASE, five other databases and two trials registers to June 2013, together with reference checking, citation searching, handsearching …
SEARCH METHODS: We searched the Effective Practice and Organisation of Care (EPOC) Group's specialised register, CENTRAL, MEDL …
Interstitial Lung Disease.
Antoine MH, Mlika M. Antoine MH, et al. 2023 Jul 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. 2023 Jul 31. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan–. PMID: 31082128 Free Books & Documents.
Interstitial lung disease (ILD), sometimes called diffused parenchymal diseases, describes a heterogeneous collection of distinctive lung disorders classified on the grounds of shared clinical, radiographic, physiologic or pathologic factors. What makes it difficult to understand …
Interstitial lung disease (ILD), sometimes called diffused parenchymal diseases, describes a heterogeneous collection of distinctive lung di …
Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN study group.
Masson E, Zou WB, Pu N, Rebours V, Génin E, Wu H, Lin JH, Wang YC; Franco-Chinese GREPAN Study Group; Li ZS, Cooper DN, Férec C, Liao Z, Chen JM. Masson E, et al. Pancreatology. 2023 Aug;23(5):491-506. doi: 10.1016/j.pan.2023.04.004. Epub 2023 Apr 20. Pancreatology. 2023. PMID: 37581535
METHODS: All currently reported PRSS1 variants (derived primarily from two databases) were manually reviewed with respect to their clinical genetics, functional analysis and population allele frequency. They were classified by variant type and pathological mechanism within …
METHODS: All currently reported PRSS1 variants (derived primarily from two databases) were manually reviewed with respect to their clinical …
Fecal microbiota transplantation to maintain remission in Crohn's disease: a pilot randomized controlled study.
Sokol H, Landman C, Seksik P, Berard L, Montil M, Nion-Larmurier I, Bourrier A, Le Gall G, Lalande V, De Rougemont A, Kirchgesner J, Daguenel A, Cachanado M, Rousseau A, Drouet É, Rosenzwajg M, Hagege H, Dray X, Klatzman D, Marteau P; Saint-Antoine IBD Network; Beaugerie L, Simon T. Sokol H, et al. Microbiome. 2020 Feb 3;8(1):12. doi: 10.1186/s40168-020-0792-5. Microbiome. 2020. PMID: 32014035 Free PMC article. Clinical Trial.
The steroid-free clinical remission rate at 10 and 24 weeks was 44.4% (4/9) and 33.3% (3/9) in the sham transplantation group and 87.5% (7/8) and 50.0% (4/8; one patient loss of follow-up while in remission at week 12 and considered in flare at week 24) in the FMT group …
The steroid-free clinical remission rate at 10 and 24 weeks was 44.4% (4/9) and 33.3% (3/9) in the sham transplantation group and 87. …
5,783 results